Claims:

1. An aqueous pharmaceutical composition comprising a surfactant and vitamin A palmitate, wherein:

i) the surfactant forms a plurality of micelles;

ii) substantially all of the vitamin A palmitate is disposed within a plurality of hydrophobic portions of the plurality of micelles;

iii) the vitamin A palmitate is present in the aqueous pharmaceutical composition at a concentration of 0.03 to 4.0%w/w;

iv) the weight of the surfactant present in the aqueous pharmaceutical composition is 4.0 or more times the weight of the vitamin A palmitate present in the aqueous pharmaceutical composition; and

v) optionally, the pH of the aqueous pharmaceutical composition is 7.0 to 7.5 and the aqueous pharmaceutical composition comprises a conjugate base of a pharmaceutically acceptable acid and/or a conjugate acid of a pharmaceutically acceptable base; and

vi) each of the micelles of the plurality of micelles has a diameter of less than or equal to 500 nm.

2. The aqueous pharmaceutical composition according to claim 1, wherein the weight of the surfactant present in the aqueous pharmaceutical composition is 4.0 to 5.0 times the weight of the vitamin A palmitate present in the aqueous pharmaceutical composition.

3. The aqueous pharmaceutical composition according to claim 1 or claim 2, wherein the surfactant is selected from polysorbate 20, polysorbate 60, polysorbate 80, stearyl alcohol, a polyethylene glycol derivative of hydrogenated castor oil, a polyethylene glycol derivative of hydrogenated castor oil, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, polyoxyethylene (20) oleyl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (10) cetyl ether, polyoxyethylene (10)

oleyl ether, polyoxyethylene (100) stearyl ether, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, polyoxyethylene (4) lauryl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (2) cetyl ether , caprylocaproyl polyoxyl-8 glyceride, polyethylene glycol (20) stearate, polyethylene glycol (40) stearate, polyethylene glycol, polyethylene glycol (8) stearate, and polyoxyl 40 stearate, and mixtures thereof.

4. The aqueous pharmaceutical composition according to any one of claims 1 to 3, wherein the surfactant comprises polysorbate 80.

5. The aqueous pharmaceutical composition according to any one of claims 1 to 4, wherein each micelle of the plurality of micelles has a diameter of less than or equal to 250 nm.

6. The aqueous pharmaceutical composition according to any one of claims 1 to 5, wherein each micelle of the plurality of micelles has a diameter of less than or equal to 100 nm.

7. The aqueous pharmaceutical composition according to any one of claims 1 to 6, wherein the vitamin A palmitate is present in the aqueous pharmaceutical composition at a concentration of 0.3% to 3.0% vitamin A palmitate.

8. The aqueous pharmaceutical composition according to any one of claims 1 to 7, wherein the vitamin A palmitate is present in the aqueous pharmaceutical composition at a concentration of 2.5% to 3.0% vitamin A palmitate.

9. The aqueous pharmaceutical composition according to any one of claims 1 to 8, wherein the surfactant comprises polysorbate 80 and the fatty acid content of the polysorbate 80 is greater than or equal to 98% oleic acid.

10. The aqueous pharmaceutical composition according to any one of claims 1 to 9, wherein the conjugate base of a pharmaceutically acceptable acid comprises the

conjugate base of citric acid and the conjugate acid of a pharmaceutically acceptable base comprises the conjugate acid of sodium hydroxide.

11. The aqueous pharmaceutical composition according to any one of claims 1 to 10, wherein the aqueous pharmaceutical composition is suitable for parenteral administration.

12. The aqueous pharmaceutical composition according to any one of claims 1 to 11, wherein the aqueous pharmaceutical composition is suitable for oral administration.

13. The aqueous pharmaceutical composition according to any one of claims 1 to 12, wherein the aqueous pharmaceutical composition has a clarity of that of water.

14. The aqueous pharmaceutical composition according to any one of claims 1 to 13, wherein the aqueous pharmaceutical composition has a clarity meeting or exceeding the standard set forth the European Pharmacopeia 7.0.

15. The aqueous pharmaceutical composition according to any one of claims 1 to 14, wherein the plurality of micelles is permanently miscible.

16. The aqueous pharmaceutical composition according to any one of claims 1 to 15, wherein the aqueous pharmaceutical composition is capable of being sterile filtered.

17. The aqueous pharmaceutical composition according to any one of claims 1 to 16, for use in the treatment or prophylaxis of a vitamin A deficiency disorder in a subject in need thereof.

18. The aqueous pharmaceutical composition according to any of claims 1 to 17, wherein the vitamin A deficiency disorder is selected from neonatal sepsis, hospital-

acquired sepsis, sepsis from premature rupture of membranes, bronchopulmonary dysplasia, retinopathy of prematurity, measles, meningitis, pneumonia, necrotizing enterocolitis, a viral infection and a bacterial infection, and a combination of such disorders.

19. A process for preparing an aqueous pharmaceutical composition comprising:

(1) providing a mixture of vitamin A palmitate and a surfactant, wherein the weight of the surfactant is 4 to 5 times the weight of the vitamin A palmitate;

(2) warming the mixture to a temperature of 40°C to 70°C and agitating the warmed mixture until homogeneous;

(3) adding water over 5 to 90 minutes with agitation to afford a homogeneous intermediate state, wherein the weight of the water is from 20% to 80% of the weight of the mixture of step (1), and wherein the water optionally has a temperature of 40°C to 70°C;

(4) cooling the mixture of step (3) to a temperature of 15°C to 40°C;

(5) adding water to achieve the desired final concentration of vitamin A palmitate, agitating the resultant mixture for 5 minutes to 6 hours to afford a stable mixture comprising a micelle of the desired diameter; and

optionally adjusting the pH of the stable mixture from 7.0 to pH 7.5 by addition of a pharmaceutically acceptable acid and/or a pharmaceutically acceptable base; and

(6) passing the mixture of step (5) through a filter having a pore size of 0.1 to 0.22 microns.

20. The pharmaceutical composition prepared by the process according to claim 19.

21. The aqueous pharmaceutical composition according to claim 19 for use in the treatment or prophylaxis of a vitamin A deficiency disorder in a subject in need thereof.

22. The process according to claim 19, wherein the surfactant comprises polysorbate 80.